Professor Stricker presented via Zoom his findings on focal ablation therapy (IRE) to the Thai Urological Association
The focus of Professor Stricker’s presentation was on giving up-to-date results based on his 800 plus cases of focal therapy ablation using the NanoKnife© Irreversible Electroporation Therapy (IRE).
The main finding presented was that approximately 85% of patients who are suitable for NanoKnife IRE therapy will mostly have minimal side-effects and at seven to ten years will have avoided surgery or radiotherapy. Professor Stricker went on to explain that this was only suitable for certain patients with localised intermediate-risk prostate cancer.
He also mentioned that the registry that he has set up across Australasia now has over 1000 patients in it and this will be the source of further information about IRE outcomes.
